Category Archives: Embryonic Stem Cells


Gaining clarity on the ethical issues of a possible COVID-19 vaccine – Pursuit

Republish this article

We believe in the free flow of information. This work is licensed under a Creative Commons Attribution-No Derivatives 3.0 Australia (CC BY-ND 3.0 AU), so you can republish our articles for free, online or in print.

All republished articles must be attributed in the following way and contain links to both the site and original article: This article was first published on Pursuit. Read the original article.

Dr Christopher Gyngell, Dr Michelle Taylor-Sands and Professor Megan Munsie

On 20 August 2020, three prominent religious leaders in Australia wrote to the Prime Minister to express concerns about the ethical dilemma associated with calls to make vaccination for COVID-19 mandatory.

This followed the announcement that the Australian Government had signed a letter of intent to secure supply of the AstraZeneca/Oxford University COVID-19 vaccine should the current clinical trials prove successful.

The central concern is that the production of the vaccine uses a cell line HEK-293 that is cultured from electively aborted human foetus and that the Australian Government should support supply of an alternative uncontroversial vaccine if mandatory vaccination for COVID-19 is to be introduced.

Given the implications for potential take-up of a vaccine, its important to unpack this concern as well as the general ethical concerns from using human cell lines.

Manufacturing of the Oxford vaccine involves human kidney cells. These cells are used as factories to make the component of the vaccine that carries genes from the SARS-CoV-2 virus with the aim of triggering an immune response to protect the recipient when injected.

The type of cells used are descendants of cells first obtained in the early 1970s, from a foetus which was probably electively aborted (although records have now been lost).

These cells were cultured in the laboratory to produce what is called a cell line, a population of cells that have adapted to grow continuously in culture while retaining uniform characteristics.

Once created, cell lines are usually shared with researchers in different laboratories and referred to by a simple reference code. In the case of this foetal cell line it was called HEK-293.

Even though the descendants of foetal cells are used to produce the vaccine, the actual vaccination does not contain any foetal cells, or pieces of foetal DNA.

This cell line, and others like it, are commonly used in medical research. Indeed of the six COVID-19 vaccine candidates in development across the globe use human foetal cell lines.

Foetal cells derived from elective terminations of pregnancy have been commonly used in scientific research since the 1960s.

Their unique properties, such as an ability to be grown easily in the lab into cell lines, and the extensive knowledge about these cells gathered over decades of research, has seen them used to manufacture many vaccines, including those commonly used against rubella, chickenpox, hepatitis A, and shingles.

Again like in the production of the Oxford vaccine, there is no residual foetal cells or DNA in the actual vaccines.

Foetal cells have also been used to make approved drugs against diseases including haemophilia, rheumatoid arthritis, and cystic fibrosis and to study infectious diseases like Zika and HIV.

It is important to clarify that while foetal cells are sometimes referred to as embryonic cell lines, this should not be confused with the use of human embryos or creation of embryonic stem cells.

Foetal cells are obtained from donated tissue following termination of pregnancy or spontaneous miscarriage, while embryonic stem cells are obtained from donated human embryos originally created in the course of infertility treatment at an IVF clinic.

The term embryonic can refer to a stage of development both before and after a pregnancy is established.

HEK-293 cell line may be correctly described as being from embryonic kidney cells but is quite different to the use of human embryos to make an embryonic stem cell line that could be used in research to understand kidney disease or how kidneys develop.

The use of human embryos in research is highly regulated in Australia and elsewhere across the globe. While advances in stem cell research have reduced the need for foetal cells in certain areas of research, there remains a clear need for foetal tissue research.

The letter to the Prime Minister cites concerns that using products from the HEK-293 line amounts to benefiting from an elective termination, and therefore makes one complicit in a moral wrong.

This is only a concern for people who believe terminating a pregnancy is a moral wrong. This position would have far-ranging implications for public health, beyond the use of the Oxford vaccine.

Many currently available vaccines, and some other COVID-19 vaccine candidates, are produced using foetal cell lines.

More fundamentally the use of foetal cells lines is a ubiquitous part of medical research, leading to many techniques and drugs that are commonly used in medicine and have contributed to advances that have saved many lives.

Even those who have no moral objection to elective termination of pregnancy may have other concerns about the use of human or animal cell lines.

Ethical standards have improved greatly in the last few decades, and we need to confront some ethically suspect practices of the past. But one way we should respond to past bad practices is to learn from them and improve our standards.

In Australia, research using foetal tissue is subject to careful oversight under the National Statement on Ethical Conduct in Human Research (National Statement), which exemplifies the values of respect, research merit and integrity, justice, and beneficence.

The National Statement acknowledges that human research carries a potential risk of harm, discomfort and/or inconvenience for participants and/or others and therefore requires that the potential benefits of the research justify any risks involved.

It also requires that those who conscientiously object to being involved in conducting research with foetal tissue are not compelled to participate or put at a disadvantage because of their objection. This concession reflects the value of respect for human life and the beliefs of those involved in research.

While one of the letters authors, Sydneys Archbishop Anthony Fisher, has subsequently stressed that he does not think that it would be unethical to use this vaccine if there is no alternative available, and that he wont be critical of anyone who uses the vaccine.

His call for ethically untainted alternative might be difficult to meet given the long and deep role that foetal tissue has played in medical research.

Its unlikely that any COVID-19 vaccine will be entirely free from the use foetal cell lines, as some knowledge gained from those cell lines will go into any vaccine that is created.

While this issue may not be easily resolved, it is important to continue discussing ethical issues as we race to develop safe and effective treatments and/or vaccines for COVID-19.

As acknowledged in the National Statement, the risks and benefits of human research must always be considered to promote ethically good research.

The development of a safe and effective vaccine for COVID-19 carries significant benefit for the community, thereby promoting the values of research merit and integrity and beneficence.

Another core value in the National Statement is justice, which includes procedural justice (fair treatment in the recruitment of participants and the review of research) and distributive justice (fair distribution of the benefits and burdens of research).

As new vaccines are developed, it will therefore be important to uphold rigorous ethical standards in both laboratory and clinical research and ensure equitable distribution of the vaccine on a global scale.

Banner: Getty Images

The Media Office is staffed from 8am5pm Monday to Friday.

The University has a television and radio studio to facilitate live and prerecorded broadcast quality interviews with media. You can also Find an expert for commentary.

Visit link:
Gaining clarity on the ethical issues of a possible COVID-19 vaccine - Pursuit

Stem Cells Market is Expected to Thrive at Impressive CAGR by 2025 – Scientect

This report studies the Stem Cells market size (value and volume) by players, regions, product types and end industries, history data 2013-2017 and forecast data 2018-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porters Five Forces Analysis.

Request Sample copy of this report athttps://www.precisionbusinessinsights.com/request-sample?product_id=30511

Stem cells are a class of undifferentiated cells that are able to differentiate into specialized cell types. Commonly, stem cells come from two main sources: Embryos formed during the blastocyst phase of embryological development (embryonic stem cells) and Adult tissue (adult stem cells).

Both types are generally characterized by their potency, or potential to differentiate into different cell types (such as skin, muscle, bone, etc.).

Stem Cells market, by technology, is Cell Acquisition, Cell Production, Cryopreservation, Expansion, and Sub-Culture. Stem Cell Therapy in China is not mature, so in this report we mainly cover Stem Cell Banking market.

Stem Cells market, by technology, is Cell Acquisition, Cell Production, Cryopreservation, Expansion, and Sub-Culture. Stem Cell Therapy in China is not mature, so in this report we mainly cover Stem Cell Banking market.

RequestCustomization copy of this report athttps://www.precisionbusinessinsights.com/request-customisation?product_id=30511

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Stem Cells in these regions, from 2013 to 2025, covering

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)

South America (Brazil etc.)

Middle East and Africa (Egypt and GCC Countries)

The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market include

CCBC

Vcanbio

Boyalife

Beikebiotech

By the product type, the market is primarily split into

Umbilical Cord Blood Stem Cell

Embryonic Stem Cell

Adult Stem Cell

Other

By the end users/application, this report covers the following segments

Diseases Therapy

Healthcare

We can also provide the customized separate regional or country-level reports, for the following regions:

North America

United States

Canada

Mexico

Asia-Pacific

China

India

Japan

South Korea

Australia

Indonesia

Singapore

Malaysia

Philippines

Thailand

Vietnam

Rest of Asia-Pacific

Europe

Germany

France

UK

Italy

Spain

Russia

Rest of Europe

Central & South America

Brazil

Rest of Central & South America

Middle East & Africa

GCC Countries

Turkey

Egypt

South Africa

Rest of Middle East & Africa

The study objectives of this report are:

To study and analyze the global Stem Cells market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.

To understand the structure of Stem Cells market by identifying its various subsegments.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Focuses on the key global Stem Cells manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Stem Cells with respect to individual growth trends, future prospects, and their contribution to the total market.

To project the value and volume of Stem Cells submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

About Us:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights. We at Precision Business Insights are passionate about market research and love to do the things in an innovative way. Our team is a big asset for us and great differentiating factor. Our company motto is to address client requirements in the best possible way and want to be a part of our client success. We have a large pool of industry experts and consultants served a wide array of clients across different verticals. Relentless quest and continuous endeavor enable us to make new strides in market research and business consulting arena.

Contact Us:

[emailprotected]

PH +1-866-598-1553

View post:
Stem Cells Market is Expected to Thrive at Impressive CAGR by 2025 - Scientect

Study reveals genetic mutations may be linked to infertility, early menopause – Sify News

The study appears in the journal of Science Advances. The human gene -- called nuclear envelope membrane protein 1 (NEMP1) -- is not widely studied. In animals, mutations in the equivalent gene had been linked to impaired eye development in frogs. When the gene is missing in fruit flies, roundworms, zebrafish and mice, the animals are infertile or lose their fertility unusually early but appear otherwise healthy. The researchers who made the new discovery were not trying to study fertility at all. Rather, they were using genetic techniques to find genes involved with eye development in the early embryos of fruit flies. "We blocked some gene expression in fruit flies but found that their eyes were fine," said senior author Helen McNeill, PhD, the Larry J. Shapiro and Carol-Ann Uetake-Shapiro Professor and a BJC Investigator at the School of Medicine. "So, we started trying to figure out what other problems these animals might have. They appeared healthy, but to our surprise, it turned out they were completely sterile. We found they had substantially defective reproductive organs." Though it varied a bit by species, males and females both had fertility problems when missing this gene. And in females, the researchers found that the envelope that contains the egg's nucleus -- the vital compartment that holds half of an organism's chromosomes -- looked like a floppy balloon. "This gene is expressed throughout the body, but we didn't see this floppy balloon structure in the nuclei of any other cells," said McNeill, also a professor of developmental biology. "That was a hint we'd stumbled across a gene that has a specific role in fertility. We saw the impact first in flies, but we knew the proteins are shared across species. With a group of wonderful collaborators, we also knocked this gene out in worms, zebrafish and mice. It's so exciting to see that this protein that is present in many cells throughout the body has such a specific role in fertility. It's not a huge leap to suspect it has a role in people as well." To study this floppy balloon-like nuclear envelope, the researchers used a technique called atomic force microscopy to poke a needle into the cells, first penetrating the outer membrane and then the nucleus's membrane. The amount of force required to penetrate the membranes gives scientists a measure of their stiffness. While the outer membrane was of normal stiffness, the nucleus's membrane was much softer. "It's interesting to ask whether stiffness of the nuclear envelope of the egg is also important for fertility in people," McNeill said. "We know there are variants in this gene associated with early menopause. And when we studied this defect in mice, we see that their ovaries have lost the pool of egg cells that they're born with, which determines fertility over the lifespan. So, this finding provides a potential explanation for why women with mutations in this gene might have early menopause. When you lose your stock of eggs, you go into menopause." McNeill and her colleagues suspect that the nuclear envelope has to find a balance between being pliant enough to allow the chromosomes to align as they should for reproductive purposes but stiff enough to protect them from the ovary's stressful environment. With age, ovaries develop strands of collagen with the potential to create mechanical stress not present in embryonic ovaries. "If you have a softer nucleus, maybe it can't handle that environment," McNeill said. "This could be the cue that triggers the death of eggs. We don't know yet, but we're planning studies to address this question." Over the course of these studies, McNeill said they found only one other problem with the mice missing this specific gene: They were anaemic, meaning they lacked red blood cells. "Normal adult red blood cells lack a nucleus," McNeill said. "There's a stage when the nuclear envelope has to condense and get expelled from the young red blood cell as it develops in the bone marrow. The red blood cells in these mice aren't doing this properly and die at this stage. With a floppy nuclear envelope, we think young red blood cells are not surviving in another mechanically stressful situation." The researchers would like to investigate whether women with fertility problems have mutations in NEMP1. To help establish whether such a link is causal, they have developed human embryonic stem cells that, using CRISPR gene-editing technology, were given specific mutations in NEMP1 listed in genetic databases as associated with infertility. "We can direct these stem cells to become eggs and see what effect these mutations have on the nuclear envelope," McNeill said. "It's possible there are perfectly healthy women walking around who lack the NEMP protein. If this proves to cause infertility, at the very least this knowledge could offer an explanation. If it turns out that women who lack NEMP are infertile, more research must be done before we could start asking if there are ways to fix these mutations -- restore NEMP, for example, or find some other way to support nuclear envelope stiffness." (ANI)

Here is the original post:
Study reveals genetic mutations may be linked to infertility, early menopause - Sify News

Scientists discover protein linked to depression and brain disorders – The Irish Times

It is expected this breakthrough will. . . lead to earlier diagnosis and better treatments for people with certain brain disorders, says Dr Vijay Tiwari at Queens University Belfast.

Earlier diagnosis and better treatments for people with depression and certain brain disorders may be possible following a research breakthrough involving Belfast-based scientists.

They have found how a specific protein plays a crucial role in the generation of neurons the nerve cells that relay electrical signals it the brain. This was made possible by focusing on a specific time and location during brain development, and how its disruption can lead to intellectual disability and depression in adults.

A research team led by Queens University Belfast (QUB) in collaboration with the Centre for Regenerative Therapies at Dresden University in Germany have published their findings in the journal Genes & Development.

It is expected this breakthrough will have a major impact on our fundamental understanding of brain development and lead to earlier diagnosis and better treatments for people with certain brain disorders, said Dr Vijay Tiwari, who is based at the Wellcome-Wolfson Institute for Experimental Medicine at QUB.

Our study reveals the key role this protein plays during the birth of probably one of the most important cells in our body the neuron.

Brain development is a highly complex process that involves generating various types of cells at defined time points and locations during embryonic development, he explained. Any kind of interference during these processes is known to cause diseases including a range of intellectual disabilities.

Among these brain cell types, neurons are the working unit of the brain, designed to transmit information to other nerve cells and various tissues in the body, such as the muscles as well as storage of memory in our brain, he added.

While the field has rapidly advanced, the mechanisms creating the birth of neurons from their mother cells, called neural stem cells, in time and space during development has not been well understood until now.

To conduct their study, the researchers looked at brain samples to closely determine the development of various cell types within the brain.

The study showed how the presence of a specific protein (called Phf21b), within a defined time window of brain development and in a specific location in the brain, signals the birth of neurons from neural stem cells in the right place and at the right time, said Dr Tiwari, who is a molecular biologist working in neuroscience.

The researchers found that removal of Phf21b stopped production of neurons from neural stem cells and led to severe defects in brain development. They also found the importance of this protein, in particular in the folding of DNA in cells going on to form neurons.

Understanding how a cell type in the brain is born at a specific point and in a specific place during development is crucial in our understanding how neurological issues arise later in life. We hope this discovery will pave the way for earlier diagnosis, earlier interventions and better treatment for people with a brain disorder, such as depression, he said.

Their research suggested screening for certain genetic variants would enable earlier diagnosis, in contrast to a scenario where depression in adults is not usually detected until a person is seriously depressed.

Read the original post:
Scientists discover protein linked to depression and brain disorders - The Irish Times

Global Stem Cells Market Report Forecast to 2025 by Global Market Insights, Key Companies and Driving Trends| CCBC, Vcanbio, Boyalife, Beikebiotech -…

Global Stem Cells Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)

Global Stem Cells Market Report offers an entire study of the Impact of COVID-19 on Stem Cells Market, Industry Outlook, Opportunities in Market, and Expansion By 2025 and also taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of this also as a future scenario of the worldwide Stem Cells industry. Research techniques like PESTLE and SWOT analysis are deployed by the researchers. They need also provided accurate data on Stem Cells production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding of the general existing and future market situation.

>>> Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Stem Cells Market:

Stem Cells Market competition by top manufacturers/Key player Profiled: CCBC, Vcanbio, Boyalife, Beikebiotech

The study objectives of Stem Cells Market report are: 1.To identify opportunities and challenges for Global Stem Cells. 2.To provide insights about factors affecting market growth. To analyze the Stem Cells market based on various factors- price analysis, supply chain analysis, SWOT analysis, etc. 3.To identify and analyze the profile of leading players involved within the manufacturing of worldwide Stem Cells. 4.To provide country-level analysis of the market regarding the present Stem Cells market size and future prospective. 5.To examine competitive developments like expansions, new product launches, mergers & acquisitions, etc., in Global Stem Cells. 6.To provide a detailed analysis of the market structure alongside forecast of the varied segments and sub-segments of the worldwide Stem Cells market.

By Types, the Stem Cells Market can be Splits into:

Umbilical Cord Blood Stem Cell Embryonic Stem Cell Adult Stem Cell Other

By Applications, the Stem Cells Market can be Splits into:

Diseases Therapy Healthcare

The global Stem Cells market was valued at $XX million in 2019, and MAResearch analysts predict the global market size will reach $XX million by the end of 2029, growing at a CAGR of XX% between 2019 and 2029.

This report provides detailed historical analysis of global market for Stem Cells from 2014-2019, and provides extensive market forecasts from 2020-2029 by region/country and subsectors. It covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the Stem Cells market.

Click Here For Best Discount: https://www.reporthive.com/request_customization/2287218

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific) Europe (Germany, the UK, France, and Rest of Europe) North America (the US, Mexico, and Canada) Latin America (Brazil and Rest of Latin America) Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

Global Stem Cells Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Stem Cells Market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons To Buy: Make strategic business decisions using in-depth historic and forecast market data associated with the Stem Cells market, and every category within it. Extensive price charts draw particular pricing trends within recent years Position yourself to realize the most advantage of the Stem Cells markets growth potential To understand the latest trends of the Stem Cells market To understand the impactful developments of key players within the market, their strategic initiatives and comprehensively study their core competencies

For Customised Template PDF Report: https://www.reporthive.com/request_customization/2287218

Table of Contents

Report Overview:It includes major players of the global Stem Cells Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Stem Cells Market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Stem Cells Market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Stem Cells Market by application, it gives a study on the consumption in the global Stem Cells Market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Stem Cells Market are profiled in this section. The analysts have provided information about their recent developments in the global Stem Cells Market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Stem Cells Market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Stem Cells Market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Stem Cells Market.

Key Findings: This section gives a quick look at important findings of the research study.

About Us: Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Contact Us:

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]ve.com

Phone: +1 312-604-7084

View post:
Global Stem Cells Market Report Forecast to 2025 by Global Market Insights, Key Companies and Driving Trends| CCBC, Vcanbio, Boyalife, Beikebiotech -...

Global Cell Isolation Market Report Promising Growth of CAGR of 17.91% , Analysis of Top companies and their Share, Size and Scope – Scientect

Global Cell Isolation Market is expected to grow at a CAGR of 17.91% from 2020 to 2023 and Cell Isolation Market report explains why and how it is going to achieve this growth. It provides vital information on every parameter which is required for making strategic decisions and development of every business in Cell Isolation industry. It would come handy to understand market situations, top competitors with their focused segments, regions etc.

Request a Sample Copy of the Report For COVID-19 Impact Analysis onCell Isolation Market

About Cell Isolation Market The rise in demand for clinical diagnosis is one of the key factors anticipated to drive the cell isolation market growth during the forecast period. To effectively treat various diseases using genetic engineering tools, early diagnosis is essential. Genetic engineering tools provide diagnostic enzymes such as cholesterol oxidase and xylitol oxidase. These diagnostic enzymes identify specific cells like cells with high levels of cholesterol. When blood levels of these particular enzymes increase significantly, it indicates a probable site for tissue damage, which releases these enzymes in the blood. These enzymes are used in assays using samples of serum or urine. The isolation of these enzymes can provide the required enzymes for clinical diagnosis. Thus, genetic engineering tools are useful, precise, and economical for researchers and healthcare providers to diagnose patients. Research analysts have predicted that the cell isolation market will register a CAGR of almost 19% by 2023.

TheTop Manufacturers/playersincluding:-

Agilent Technologies Inc., Becton Dickinson and Co., Merck KGaA, QIAGEN NV, Thermo Fisher Scientific Inc.

Get a Sample PDF of report https://www.360marketupdates.com/enquiry/request-sample/14035352

Market Segment of Cell Isolation Industry:

Market Overview

Competitive Landscape

Feel Free to Ask Question Before Purchasing the Report at https://www.360marketupdates.com/enquiry/pre-order-enquiry/14035352

Cell Isolation Market Report provides comprehensive analysis of-

Key Summary of Cell Isolation Market Growth Report:

In our market size and forecast determination efforts, in-depth secondary research was initially completed to realize an honest perspective of the market in each region. Extensive primary research was also administered by interviewing key executives from the industry. These interviews helped us to fill-in the info gaps after secondary research. Several secondary sources like encyclopedia, directories, and databases are wont to identify and collect information useful for this extensive techno-commercial study.

Key Questions Answered in ROY Cell Isolation Market Report:

Purchase this report (Price2500 USD for a single-user license)@ https://www.360marketupdates.com/purchase/14035352

In the end, the Cell Isolation Market report makes some important proposals for a new project of the Cell Isolation Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of Global Cell Isolation Industry covering all important parameters.

Table of Contents included in Cell Isolation Market ROY Report

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Market landscape

PART 06: Market segmentation by end-user industry

PART 07: Market segmentation by application

PART 08: Geographical Segmentation

PART 09: A Decision framework

PART 10: Impact of drivers and challengesAnd Many More Parts Covered.

Be sure to follow on Linkedin at @360 Market Updatesfor more on growth research and the research market.

CONTACT US

Name: Mr. Ajay More

Email: [emailprotected]

Organization: 360 Market Updates

Phone: +1 424 253 0807 / + 44 203 239 8187

OUR OTHER REPORTS:

Anti Fog Insulators Market Report 2020 Indepth Analysis on Market Share, Size, Growth Rate and Factors, Future Developments and Prospects

Running Socks Market 2020 Global Industry Growth Rate, Share, Size, Price, Prospect, Developments and Forecast till 2025

Food Grade Vitamin D Market Report 2020 Indepth Analysis on Market Share, Size, Growth Rate and Factors, Future Developments and Prospects

Elderly Care Services Market Report 2020 Indepth Analysis on Market Share, Size, Growth Rate and Factors, Future Developments and Prospects

Premium High-Security Door Market 2020 Global Industry Growth Rate, Share, Size, Price, Prospect, Developments and Forecast till 2026

Global Xanthan Gum Market 2020 Growth Overview, Top Manufacturers, Latest Trends, Future Prospects and Forecast 2025

View original post here:
Global Cell Isolation Market Report Promising Growth of CAGR of 17.91% , Analysis of Top companies and their Share, Size and Scope - Scientect

ASU engineers get to the heart of organs-on-a-chip – ASU Now

August 17, 2020

Denver is known for its relatively mild climate and its four distinct seasons. Its also known for its temperature fluctuations over the course of a day or even hours. But what does that mean for the citys residents and for that matter, the rest of the inhabitants of the continental United States when it comes to temperature extremes?

Thats what Ashley Broadbentwanted to know. Specifically, he wanted to know how populations throughout the United States will experience heat and cold during the 21st century.

So, Broadbent, an assistant research professor in Arizona State Universitys School of Geographical Sciences and Urban Planning, used state-of-the-art modeling tools to analyze how three key variables would affect human exposure to extreme temperatures from the beginning of this century to its end.

He and his collaborator Matei Georgescu, an associate professor in the School of Geographical Sciences and Urban Planning, concentrated on the following three key factors: climate change brought about by greenhouse gas emissions, urban development-induced impacts arising from the growth of cities, and population change in individual cities.

The paper, "The motley drivers of heat and cold exposure in 21st century U.S. cities," was published onlineAug. 17 in the Proceedings of the National Academy of Sciences. It is the first study of its kind to consider population-weighted heat and cold exposure that directly and simultaneously account for greenhouse gas and urban development-induced warming.

Graphic by Alex Davis/ASU Media Relations and Strategic Communications

To describe how these three variables would affect temperatures, and in turn populations, Broadbent, Georgescu and co-author Eric Scott Krayenhoff, assistant professor at the University of Guelph, Ontario, in Canada, used a metric they dubbed person-hours, to describe humans exposure to extreme heat and cold.

Its an intuitive metric, Broadbent said. For example, when one person is exposed to one hour of an extreme temperature, that exposure equals one person-hour of exposure. Likewise, if 10 people are exposed to 10 hours of an extreme temperature, that exposure equals 100 person-hours.

I think this definition is more representative of what people experience, which is what this study is about versus a study that simply communicates temperature changes without any human element attached to it, Broadbent said.

Overall, the researchers found that the average annual heat exposure at the start of this century in the United States was about 5.2 billion person-hours. Assuming a worst-case scenario of peak global warming, population growth and urban development, the annual heat exposure would rise to 150 billion person-hours by the end of the century, a nearly 30-fold increase.

The combined effect of these three drivers will substantially increase the average heat exposure across the United States, but heat exposure is not projected to increase uniformly in all cities across the U.S., Broadbent said. There will be hot spots where heat exposure grows sharply.

To that end, the researchers defined heat thresholds based on local city definitions, something previous studies have not done. Instead, prior studies have used fixed-temperature thresholds that may be inappropriate for some cities. Afterall, a 90-degree day in Phoenix feels much different than a 90-degree day in New York City, given relative humidity differences.

Its well-known that cities have locally defined thresholds where heat and cold cause mortality and morbidity, Broadbent explained. In other words, people die at different temperatures in different cities because what is extreme in one city may be normal in another.

Importantly, areas of the United States where human exposure would increase the most is where climate change and population increase in tandem. Meanwhile, urban development has a smaller, yet not negligible effect.

According to the results of the study, the largest absolute changes in population heat exposure are projected to occur in major U.S. metropolitan regions, such as New York, Los Angeles and Atlanta.

The study also finds the largest relativechanges in person-hours related to heat exposure are projected to occur in rapidly growing cities located in the Sun Belt, including Austin, Texas; Orlando, Florida; and Atlanta.

The increase in exposure is quite large if you look at it relative to the start of the century, Broadbent said. Some cities across the Sun Belt, according to our projections, will have 90 times the number of person-hours of heat exposure. For example, cities in Texas that see substantial population growth and strong greenhouse gas-induced climate warming could be markedly affected.

One way to prepare for increased heat exposure is to reduce greenhouse gas emissions on a global scale, which would reduce the number of hours people are exposed to extreme temperatures. Other options include localized infrastructure adaptation that provides buffering effects against rising temperatures such as planting trees, providing shade and cooling areas and constructing buildings using materials that absorb less heat.

Although the average temperature in the United States will be warmer in the future, the study finds that cold exposure will increase slightly compared with the start of the century, primarily because of population growth. While there is a generaldecreasein the number of projected extreme cold events by the end of this century, the number of individuals exposed to extreme cold is projected toincrease,as population growth means that the total number of person-hours of cold exposure will go up, Broadbent said.

Cold is currently more of a national health problem than heat, but our results suggest that by the end of the century heat exposure may become a larger health problem than cold exposure, Broadbent said. However, cold exposure will not disappear completely as the climate warms. In fact, according to one of the teams simulations, Denver is projected to have more extreme cold at the end of the century compared with the beginning, according to the study.

Thats the interesting thing about climate change. We know the average temperature is going to increase, said Broadbent. But we know less about how the extremes are going to change, and often the extremes are the most important part of our daily lives.

There are several takeaway messages from this work, but one of the central ones concerns the future resiliency of our cities, Georgescu said.

The successful steps taken will require holistic thinking that embraces contributions from urban planners, engineers, social scientists and climate scientists with a long-range vision of how we want our cities to be.

"We therefore call on cities to start asking some very foundational questions regarding the projected exposure of their constituents to future environmental change," Georgescu said. "Is the work of the urban climate modeling community being integrated into their environmental adaptation plans? If so, how, and if not, why not?

This work was funded by the National Science Foundation.

See the original post:
ASU engineers get to the heart of organs-on-a-chip - ASU Now

Stem Cell Therapy Market Landscape Assessment By Type and Analysis Current Trends by Forecast To 2025 – The Daily Chronicle

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Know the Growth Opportunities in Emerging Markets

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

The regional analysis covers:

Order this Report TOC for Detailed Statistics

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Go here to read the rest:
Stem Cell Therapy Market Landscape Assessment By Type and Analysis Current Trends by Forecast To 2025 - The Daily Chronicle

Stem Cell Therapy Market Size and Growth By Leading Vendors, By Types and Application, By End Users and Forecast to 2027 – Bulletin Line

Allosource

The market is further segmented on the basis of types and end-user applications. The report also provides an estimation of the segment expected to lead the market in the forecast years. Detailed segmentation of the market based on types and applications along with historical data and forecast estimation is offered in the report.

Furthermore, the report provides an extensive analysis of the regional segmentation of the market. The regional analysis covers product development, sales, consumption trends, regional market share, and size in each region. The market analysis segment covers forecast estimation of the market share and size in the key geographical regions.

The report further studies the segmentation of the market based on product types offered in the market and their end-use/applications.

1.Stem Cell Therapy Market, By Cell Source:

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

2.Stem Cell Therapy Market, By Therapeutic Application:

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

3.Stem Cell Therapy Market, By Type:

Allogeneic Stem Cell Therapy Market, By Application Musculoskeletal Disorders Wounds and Injuries Surgeries Acute Graft-Versus-Host Disease (AGVHD) Other Applications Autologous Stem Cell Therapy Market, By Application Cardiovascular Diseases Wounds and Injuries Gastrointestinal Diseases Other Applications

On the basis of regional segmentation, the market is bifurcated into major regions ofNorth America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.The regional analysis further covers country-wise bifurcation of the market and key players.

The research report offered by Verified Market Research provides an updated insight into the global Stem Cell Therapy market. The report covers an in-depth analysis of the key trends and emerging drivers of the market likely to influence industry growth. Additionally, the report covers market characteristics, competitive landscape, market size and growth, regional breakdown, and strategies for this market.

Highlights of the TOC of the Stem Cell Therapy Report:

Overview of the Global Stem Cell Therapy Market

Market competition by Players and Manufacturers

Competitive landscape

Production, revenue estimation by types and applications

Regional analysis

Industry chain analysis

Global Stem Cell Therapy market forecast estimation

This Stem Cell Therapy report umbrellas vital elements such as market trends, share, size, and aspects that facilitate the growth of the companies operating in the market to help readers implement profitable strategies to boost the growth of their business. This report also analyses the expansion, market size, key segments, market share, application, key drivers, and restraints.

Key Questions Addressed in the Report:

What are the key driving and restraining factors of the global Stem Cell Therapy market?

What is the concentration of the market, and is it fragmented or highly concentrated?

What are the major challenges and risks the companies will have to face in the market?

Which segment and region are expected to dominate the market in the forecast period?

What are the latest and emerging trends of the Stem Cell Therapy market?

What is the expected growth rate of the Stem Cell Therapy market in the forecast period?

What are the strategic business plans and steps were taken by key competitors?

Which product type or application segment is expected to grow at a significant rate during the forecast period?

What are the factors restraining the growth of the Stem Cell Therapy market?

Thank you for reading our report. The report is available for customization based on chapters or regions. Please get in touch with us to know more about customization options, and our team will ensure you get the report tailored according to your requirements.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080 UK: +44 (203)-411-9686 APAC: +91 (902)-863-5784 US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Link:
Stem Cell Therapy Market Size and Growth By Leading Vendors, By Types and Application, By End Users and Forecast to 2027 - Bulletin Line

AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update – Business Wire

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the second quarter ended June 30, 2020.

AgeX made strides with respect to its newly established licensing and collaboration model, which aims to embed its technology platforms across the cell therapy industry. AgeX has entered into a research license for the use of its immunotolerance UniverCyteTM technology by Sernova Corp. (Sernova), a publicly-listed Canadian regenerative medicine therapeutics company. It also entered a Manufacturing, Marketing, and Distribution Agreement with Pluristyx, Inc. (Pluristyx), an advanced therapy tools and services company serving customers in the fields of regenerative medicine and cellular and gene therapies. In addition, AgeX signed a letter of intent with ImStem Biotechnology (ImStem), for ImStem to utilize AgeXs ESI-brand pluripotent stem cells to derive a cell therapy product for potential use in the treatment of COVID-19 and as well acute respiratory distress syndrome (ARDS) from non-COVID-19 causes.

We are working diligently to position our subsidiary Reverse Bioengineering to optimize the potential of induced tissue regeneration (iTR) technology, said Michael West, CEO of AgeX. We believe this technology offers a powerful new modality to treat age-related degenerative diseases by reversing developmental aging in a tissue, thereby unlocking an innate capacity of tissues to regenerate scarlessly.

AgeX completed its restructuring to streamline its operations to allow efficient usage of capital in the current pandemic environment as well to meet near-term strategic company priorities of deriving value and generating preclinical and ultimately clinical data from our technology platforms through external licensing and collaboration agreements. In the longer-term, AgeX remains committed to in-house product development of AgeX-BAT1 and AgeX-VASC1. AgeX is considering options to bring capital into the company.

AgeX has made excellent progress in terms of its collaboration and licensing model, closing five deals since the beginning of the year so far, said Greg Bailey M.D., Chairman of AgeX. The deals have spanned all three of our technology platforms of UniverCyte for the generation of universal cells, PureStem for the derivation and manufacturing of therapeutic cells, and AgeX ESI pluripotent stem cells to act as a source material for cellular therapies. All these deals show the value industry and academia see in our offerings.

Q2 Highlights

Liquidity and Capital Resources

AgeX is in need of additional capital to finance its operations. On March 30, 2020, AgeX entered into a Secured Convertible Facility Agreement (the New Loan Agreement) with Juvenescence Limited pursuant to which AgeX may borrow funds from time to time. As of August 14, 2020, AgeX has borrowed $3.5 million and may draw additional funds from time to time subject to Juvenescences discretion, prior to the contractual repayment date on March 30, 2023. AgeX may not draw down more than $1.0 million in any single draw. More information about the New Loan Agreement can be found in AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for the periods ended March 31, 2020 and June 30, 2020 filed with the Securities and Exchange Commission on March 30, 2020, May 14, 2020, and August 14, 2020 respectively.

On April 13, 2020, AgeX obtained a loan in the amount of $432,952 from Axos Bank under the Paycheck Protection Program (the PPP Loan). The PPP Loan bears interest at a rate of 1% per annum. No payments will be due on the PPP Loan during a six month deferral period commencing on the date of the promissory note. Commencing one month after the expiration of the deferral period, and continuing on the same day of each month thereafter until the maturity date of the PPP Loan, monthly payments of principal and interest will be due, in an amount required to fully amortize the principal amount outstanding on the PPP Loan by the maturity date. The maturity date is April 13, 2022. The principal amount of the PPP Loan is subject to forgiveness under the Paycheck Protection Program (PPP) to the extent that PPP Loan proceeds are used to pay expense permitted by the PPP, including payroll, rent, and utilities (collectively, Qualifying Expenses), during the time frame permitted by the PPP. AgeX believes that it has used the PPP Loan amount for Qualifying Expenses. However, no assurance is provided that AgeX will obtain forgiveness of the PPP Loan in whole or in part.

Staff Reductions

In May 2020, AgeX laid off 11 research and development personnel and consequently paid approximately $105,000 in accrued payroll and unused paid time off and other benefits and recognized approximately $194,800 in restructuring charges in connection with the reduction in staffing, consisting of contractual severance and other employee termination benefits, substantially all of which have been settled in cash. The staff reductions followed AgeXs strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets resulting from the COVID-19 pandemic.

Going Concern Considerations

As required under Accounting Standards Update 2014-15, Presentation of Financial Statements-Going Concern (ASC 205-40), AgeX evaluates whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date its financial statements are issued. Based on AgeXs most recent projected cash flows, and considering that loans from Juvenescence under the New Loan Agreement will be subject to Juvenescences discretion, AgeX believes that its cash and cash equivalents, the remaining $5.5 million available under the New Loan Agreement and reduction in staff in May 2020 would not be sufficient to satisfy its anticipated operating and other funding requirements for the twelve months following the filing of AgeXs Quarterly Report on Form 10-Q for the three and six months ended June 30, 2020. These factors raise substantial doubt regarding the ability of AgeX to continue as a going concern.

Second Quarter 2020 Operating Results

Revenues: Total revenues for the second quarter of 2020 were $414,000 as compared with $380,000 for the second quarter of 2019. AgeX revenues are primarily generated from subscription and advertising revenues from the GeneCards online database through its subsidiary LifeMap Sciences, Inc. Revenues in 2020 also included approximately $36,000 of allowable expenses under its research grant from the NIH as compared with $47,000 in the same period in 2019.

Operating expenses: Operating expenses for the three months ended June 30, 2020 were $3.0 million as compared to $3.8 million for the same period in 2019. On an as-adjusted basis, operating expenses for the three months ended June 30, 2020 were $2.5 million as compared to $3.1 million for the same period in 2019.

The reconciliation between GAAP and non-GAAP operating expenses is provided in the financial tables included with this earnings release.

Research and development expenses decreased by $0.3 million to $1.4 million during the three months ended June 30, 2020 from $1.7 million during the same period in 2019. The decrease was primarily attributable to the layoff of 11 research and development personnel in May 2020 and decrease in shared services from Lineage Cell Therapeutics, Inc. (Lineage) with the termination of our Shared Facilities and Services Agreement on September 30, 2019.

General and administrative expenses decreased by $0.4 million to $1.7 million during the three months ended June 30, 2020 from $2.1 million during the same period in 2019 despite an increase in head count with the employment of AgeXs own finance team since October 1, 2019. These increases were offset by a decrease in travel and related expenses with the shelter in place mandates since March 15, 2020 resulting from the COVID-19 pandemic, and the elimination of shared facilities and services fees from Lineage following the termination of the Shared Facilities and Services Agreement on September 30, 2019.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeXs core product pipeline is intended to extend human healthspan. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. In addition, with respect to AgeXs Manufacturing, Marketing and Distribution Agreement with Pluristyx there is no assurance that (i) Pluristyx will generate significant sales of AgeX ESI hESC lines, or (ii) AgeX will derive significant revenue from sales of ESI hESC lines by Pluristyx. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

AGEX THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT PAR VALUE AMOUNTS)

June 30, 2020

December 31, 2019

(Unaudited)

ASSETS

CURRENT ASSETS

Cash and cash equivalents

$

1,033

$

2,352

Accounts and grants receivable, net

235

363

Prepaid expenses and other current assets

836

1,339

Total current assets

2,104

4,054

Read more from the original source:
AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update - Business Wire